Pursuant to Regulations 30 and 34 of the SEBI (LODR) Regulations, 2015, as amended ('' Listing Regulations''), please find attached herewith the Annual Report of the Company for the FY ....
Annual Report FY25-26 and Notice of 43rd AGM on 31-Aug-2026 at 12:00 noon via VC/OAVM
- Consolidated revenue grew 36% to ₹503 crore; PAT rose 69% to ₹67.3 crore
- EBITDA margin expanded 200 bps to 24%
- Raised FY27 revenue guidance to over ₹700 crore; target ₹1,000 crore+ by FY29
- New Independent Director Swanith Kapoor appointed w.e.f. 02-Jun-2026
- Reappointment and remuneration of Whole Time Director Aditya Arora approved
- Cost auditor remuneration ratified
- Remote e-voting from 28-Aug to 30-Aug; cut-off date 24-Aug
- No dividend recommended to conserve resources
- Robust corporate governance and risk management detailed
- Subsidiary: Kwality Pharmaceuticals Africa, 51% owned
- No material regulatory or legal non-compliance reported
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 KPL — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add KPL to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Kwality Pharmaceuticals Limited
Important.
The summary above is generated automatically from Kwality Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.